Objective
The TBVAC2020 proposal builds on the highly successful and long-standing collaborations in subsequent EC-FP5-, FP6- and FP7-funded TB vaccine and biomarker projects, but also brings in a large number of new key partners from excellent laboratories from Europe, USA, Asia, Africa and Australia, many of which are global leaders in the TB field. This was initiated by launching an open call for Expressions of Interest (EoI) prior to this application and to which interested parties could respond. In total, 115 EoIs were received and ranked by the TBVI Steering Committee using proposed H2020 evaluation criteria. This led to the prioritisation of 52 R&D approaches included in this proposal.
TBVAC2020 aims to innovate and diversify the current TB vaccine and biomarker pipeline while at the same time applying portfolio management using gating and priority setting criteria to select as early as possible the most promising TB vaccine candidates, and accelerate their development. TBVAC2020 proposes to achieve this by combining creative “bottom-up” approaches for vaccine discovery (WP1), new preclinical models addressing clinical challenges (WP2) and identification and characterisation of correlates of protection (WP5) with a directive “top-down” portfolio management approach aiming to select the most promising TB vaccine candidates by their comparative evaluation using objective gating and priority setting criteria (WP6) and by supporting direct, head-to head or comparative preclinical and early clinical evaluation (WP3, WP4). This approach will both innovate and diversify the existing TB vaccine and biomarker pipeline as well as accelerate development of most promising TB vaccine candidates through early development stages. The proposed approach and involvement of many internationally leading groups in the TB vaccine and biomarker area in TBVAC2020 fully aligns with the Global TB Vaccine Partnerships (GTBVP).
Field of science
- /medical and health sciences/basic medicine/pharmacology and pharmacy/pharmaceutical drug/vaccines
Programme(s)
Call for proposal
H2020-PHC-2014-single-stage
See other projects for this call
Funding Scheme
RIA - Research and Innovation actionCoordinator
8219 PH Lelystad
Netherlands
Participants (43)
2300 Kobenhavn S
80539 Muenchen
Participation ended
B4 7ET Birmingham
1050 Elsene
9000 Gent
LL57 2DG Bangor
89081 Ulm
75724 Paris Cedex 15
75794 Paris
50009 Zaragoza
1211 Geneve
8092 Zuerich
4 Dublin
120 749 Seoul
2288 GJ Rijswijk Zh
LS2 7UE Leeds
8006 Zurich
08916 Badalona Barcelona
SN2 1FL Swindon
7600 Stellenbosch
7701 Rondebosch
WC1E 7HT London
90127 Palermo
SW7 2AZ London
2333 ZA Leiden
1050 Bruxelles
00149 Roma
2006 Sydney
OX1 2JD Oxford
Participation ended
63225 Langen
SW1P 3JR London
4001 Durban
1011 Lausanne
59019 Lille
1015 Lausanne
4051 Basel
00161 Roma
20850 Rockville Md
631 320 Gyeongsangnam Do
1330 Rixensart
67400 Illkirch-graffenstaden
17493 Greifswald-insel Riems
G1 1XQ Glasgow